Tsuno Takehiko, Kawaguchi Takashi, Yanaizumi Ryota, Kondo Junichi, Kojima Keiko, Igarashi Takashi, Inoue Masaki, Miura Tomofumi, Miyasato Akime, Azuma Kanako, Hamada Hiroshi, Saeki Tomoya, Mawatari Hironori, Ogura Hiroyuki, Kotani Akira, Yamaguchi Takuhiro, Hakamata Hideki
Department of Pharmacy, Yokohama City University Medical Center, Yokohama, Japan.
Department of Analytical Chemistry, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
Palliat Med Rep. 2024 Jan 19;5(1):43-52. doi: 10.1089/pmr.2023.0068. eCollection 2024.
We aimed to gain insight into psychological barriers toward initiation of strong opioid analgesic use in patients with advanced recurrent cancer.
This study included 46 patients who were prescribed with opioid analgesics for advanced recurrent cancer. The primary outcome was psychological barriers assessed using the Japanese version of the Barriers Questionnaire-II (JBQ-II). The secondary outcomes were psychological changes and pain relief one week after the induction of strong opioid analgesics.
The mean age of participants was 63.6 years. Furthermore, 26.1% had an Eastern Cooperative Oncology Group (ECOG) performance status of ≥3. The mean JBQ-II total score was 1.97 (95% confidence interval: 1.75-2.19). At the initiation of opioid therapy, there was no difference in the total scores between the baseline and one week later. Nevertheless, there was a significant difference in the subscale "disease progression" score (mean 2.97 vs. 2.59, difference in means 0.38, standard error 0.16, = 0.026). Personalized Pain Goal (PPG) was achieved in about half of the participants, and a trend toward a higher score in the subscale "harmful effects" (concern about adverse events) was observed in those who did not achieve PPG.
This study showed that patients with advanced recurrent cancer have psychological barriers to opioid induction. The relationship between the presence of psychological barriers before and after induction of opioid analgesics and the speed of pain improvement was determined. The results may provide fundamental information for prospective intervention studies to develop individualized education programs for patients with psychological barriers to opioids.Clinical Trial Registration Number UMIN000042443.
我们旨在深入了解晚期复发性癌症患者在开始使用强效阿片类镇痛药时的心理障碍。
本研究纳入了46例因晚期复发性癌症而开具阿片类镇痛药的患者。主要结局是使用日语版障碍问卷-II(JBQ-II)评估的心理障碍。次要结局是强效阿片类镇痛药诱导后一周的心理变化和疼痛缓解情况。
参与者的平均年龄为63.6岁。此外,26.1%的患者东部肿瘤协作组(ECOG)体能状态≥3。JBQ-II总分的平均值为1.97(95%置信区间:1.75 - 2.19)。在开始阿片类药物治疗时,基线与一周后的总分无差异。然而,在“疾病进展”子量表得分上存在显著差异(平均值2.97对2.59,均值差异0.38,标准误0.16,P = 0.026)。约一半的参与者实现了个性化疼痛目标(PPG),未实现PPG的参与者在“有害影响”(对不良事件的担忧)子量表上有得分更高的趋势。
本研究表明晚期复发性癌症患者在阿片类药物诱导方面存在心理障碍。确定了阿片类镇痛药诱导前后心理障碍的存在与疼痛改善速度之间的关系。这些结果可能为前瞻性干预研究提供基础信息,以便为存在阿片类药物心理障碍的患者制定个性化教育计划。临床试验注册号UMIN000042443。